Alcidion to exhibit at Blue Sky Investor Day, page-20

Hi @seekinfo



Going by these figures you're looking at approx $36million at today's price at re-listing if no performance shares are to be issued. Performance shares are issued under the following conditions:



I personally think that both of those milestones will be achieved without too much hassle considering there will be phenomenal demand in the US due to legislative changes. From what I have read and heard, the biggest issue in the US is that healthcare providers are struggling to roll this out quickly enough.

Then consider that Alcidion have a product that is superior to any other on the market in a number of ways as far as I am aware, which can provide huge savings to clients (both capex and time savings that is).

Looking forward to 2016 and hearing more of Alcidion's plans to tackle the US market. I would imagine Nathan has something interesting in mind as he has a proven track record in the US in the medical tech space and knows the market there very well.

Below shows the 2014 United States market share break-down.

This pie chart was taken from the HIMSS website which I found worthy of a browse.

http://www.himssanalytics.org/